Why is "Alectinib" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-17 06:21:26
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Alectinib (INN), sold under the brand name Alecensa, is an anticancer medication that is used to treat non-small-cell lung cancer (NSCLC). It blocks the activity of anaplastic lymphoma kinase (ALK). It is taken by mouth. It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Alectinib boosts anti-tumor efficacy of disialoganglioside 2 chimeric antigen receptor T cells in ALK -mutated neuroblastoma by suppressing programmed death-ligand 1 - Nature
-
Adjuvant Alectinib Impresses in Updated ALINA Results for ALK+ NSCLC - OncLive
-
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC - CancerNetwork
-
ALEX Trial Final Results at ESMO 2025: Alectinib Demonstrates Durable Overall Survival and Long-Term Disease Control in Advanced ALK-Positive NSCLC - Oncodaily
-
Study Investigates Alectinib Versus Crizotinib in the Adjuvant Setting for Patients With ALK+ NSCLC - Cancer Nursing Today
-
Implications of the ALINA Trial: Is It Time to Skip Adjuvant Chemotherapy in ALK-Positive NSCLC? - ASCO Daily News
-
Neoadjuvant Alectinib in a Patient With Anaplastic Lymphoma Kinase (ALK)-Mutant Stage III Lung Adenocarcinoma: A Case Report - Cureus
-
Alectinib Enhances CAR T-Cell Attack in ALK Neuroblastoma - Bioengineer.org
-
Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report - Frontiers
-
Alecensa Improves 4-Year Survival in Early ALK-Positive Lung Cancer - Cure Today
-
Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial - Nature
-
'Blow Your Mind' Survival Improvement in Advanced, Mutated NSCLC - MedPage Today
-
Beating the Odds: A Successful Pregnancy in a Patient With ALK-Rearranged Lung Cancer on Alectinib - Wiley Online Library
-
Phase III ALINA Trial Shows Adjuvant Alectinib Has ‘Clinically Meaningful’ Benefits for ALK+ NSCLC - Cancer Nursing Today
-
Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC - CancerNetwork
-
Computational drug repurposing reveals Alectinib as a potential lead targeting Cathepsin S for therapeutic developments against cancer and chronic pain - Frontiers
-
Dr Mok on Final OS Data From the ALEX Study Evaluating First-Line Alectinib in ALK+ NSCLC - OncLive
-
Study Investigates Tailored Sequencing Strategies to Extend Survival in ALK-Positive Advanced NSCLC - Cancer Nursing Today
-
Dr Lee on Disease-Free Survival Outcomes With Alectinib in ALK+ NSCLC - OncLive
-
Oncology Letters - Spandidos Publications
-
Advanced ALK-Positive NSCLC: Treatment Sequencing Insights From ASCO 2025 - Cancer Therapy Advisor
-
Postoperative Crizotinib Fails in Early Lung Cancer - MedPage Today
-
Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib - Frontiers
-
FDA Approves Alectinib for ALK-Positive Lung Cancer - National Cancer Institute (.gov)
-
ALNEO Phase II Trial Highlights Promising Role of Perioperative Alectinib in Stage III Resectable ALK-Positive NSCLC - Oncodaily
-
First Russian generic of Alecensa to be 40% cheaper than original drug - Новости GxP
-
In Early NSCLC, Biomarker Testing Appears to Be Underused - Physician's Weekly
-
CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib - Nature
-
Gene therapy shrank lung tumors 79% in mice in new cancer study - Stock Titan
-
Genprex (NASDAQ: GNPX) posts positive preclinical data on REQORSA in NSCLC - Stock Titan
-
Case Report: Locally advanced lung adenocarcinoma with a novel MIR217HG-ALK rearrangement responding to neoadjuvant alectinib - Frontiers
-
Case Report: Ocular metastasis from ALK-rearranged pulmonary adenocarcinoma presenting as a pseudo-syndrome of anterior uveitis - Frontiers
-
Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC - CancerNetwork
-
Alectinib Reduces Risk of Recurrence or Death by 76% in Early-Stage, Resected, ALK+ NSCLC - Oncology Nursing News
-
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer - The New England Journal of Medicine
-
Case Report: Metastatic colorectal cancer with ALK–CEP44 fusion and rapid resistance development - Frontiers
-
Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer - Pharmacy Times
-
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer - The New England Journal of Medicine
-
Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC - Pharmacy Times
-
Crizotinib Not Beneficial in Resected Early ALK+NSCLC - Medscape
-
Alectinib and Pembrolizumab for Non-Small Cell Lung Cancers - Medscape
-
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity - Nature
-
Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC - Targeted Oncology
-
Alectinib approved in Scotland for ALK+ lung cancer post-surgery - ALK Positive Lung Cancer UK - Oncodaily
-
Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports - Frontiers
-
CROWN Trial 5-Year Update: Lorlatinib Is the Frontrunner in the Frontline Setting - ASCO Daily News
-
FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer - National Cancer Institute (.gov)
-
Crizotinib fails to improve disease-free survival in resected early-stage ALK+ non-small cell lung cancer - Medical Xpress
-
Adjuvant alectinib is a new treatment strategy for resected ALK-positive NSCLC - ESMO Daily Reporter
-
Alectinib Approved for ALK-Positive Adjuvant NSCLC - Medscape
-
Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer - Frontiers
-
Adjuvant alectinib has been approved by the FDA for resected ALK-positive NSCLC - ESMO Daily Reporter
-
FDA Approves Alectinib for Early-Stage ALK+ NSCLC - CancerNetwork
-
Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC - OncLive
-
Dr Nieva on the Rationale for Comparing ALK Inhibitors in ALK+ NSCLC - OncLive
-
Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLC - CancerNetwork
-
Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib - Wiley Online Library
-
Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer - Nature
-
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study - The Lancet
-
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation - Nature
-
FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC - Pharmacy Times
-
FDA Grants Priority Review to Alectinib for ALK+ NSCLC - CancerNetwork
-
Brigatinib, Alectinib Produce Similar PFS After NSCLC Progression on Crizotinib - Cancer Therapy Advisor
-
FDA Approves Adjuvant Alectinib for ALK-Positive NSCLC - oncologynewscentral.com
-
Alectinib Improves DFS Over Chemotherapy in Early-Stage, ALK+ NSCLC - oncologynewscentral.com
-
Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC - CancerNetwork
-
Alectinib Fails to Boost Overall Survival in ALK-Positive Non-Small Cell Lung Cancer - CancerNetwork
-
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
-
Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC - CancerNetwork
-
These 33 Life-Saving Drugs, Including Daratumumab, Alectinib, Obinutuzumab, Now GST-Free, See List - Medical Dialogues
-
Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC - OncLive
-
ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK -Positive NSCLC - ascopost.com
-
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer - Nature
-
Alecensa (alectinib): Side effects, dosage, and more - Medical News Today
-
Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK -positive non-small-cell lung cancer - Wiley Online Library
-
Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review - Frontiers
-
VisualAbstract: Alectinib Improves Disease-Free Survival in ALK-Positive Non-Small-Cell Lung Cancer Compared to Platinum-Based Chemotherapy - 2 Minute Medicine
-
Salvage Surgery Following First-Line Alectinib for ALK-Rearranged NSCLC: Perioperative Outcomes & Pathological Response - Physician's Weekly
-
FDA Approves Adjuvant Alectinib in ALK+ NSCLC - Targeted Oncology
-
A New Molecularly Targeted Therapy for Lung Cancer - American Association for Cancer Research (AACR)
-
Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer - Wiley Online Library
-
Time to Response in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib in the Phase II NP28673 and NP28761 Studies - Oncology Nurse Advisor
-
Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC - ESMO Daily Reporter
-
Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC - OncLive
-
Alectinib Yields Better Overall Survival Than Ceritinib in ALK-Positive Non–Small Cell Lung Cancer - CancerNetwork
-
Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer - Frontiers
-
ASCO 2025 / Promising new targeted therapy in very rare pediatric cancers - Institut Curie
-
Incidence of Cardiac AEs With Alectinib Higher Than Expected in ALK+ NSCLC - Oncology Nurse Advisor
-
Substantial Meals Can Elevate Lung Cancer Drug Concentration - Cure Today
-
FDA Approves Alectinib to Treat ALK-positive Lung Cancer - respiratory-therapy.com
-
Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC - MedPage Today
-
Cancer drug alectinib less effective when taken with low-fat yogurt - Healio
-
Lorlatinib Yields No Unexpected Toxicities in ALK-Positive NSCLC - CancerNetwork
-
Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement - Haematologica
-
Diet May Have Big Effect on Common Lung Cancer Treatment - Inside Precision Medicine
-
Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma - Nature
-
Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-small cell lung cancer - Wiley Online Library
-
Updated Phase 3 ALEX Trial Data Finds Alectinib Maintains Significant Benefit in ALK+ NSCLC - CancerNetwork
-
Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers - Cancer Therapy Advisor
-
Alectinib for Relapsed/Refractory ALK+ NSCLC - OncLive
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.